LQLaura Schmidt Quinsani

Laura Schmidt Quinsani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Laura Schmidt Quinsani has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Full-spectrum cannabidiol-rich oil modulates behavior and neurochemical alterations in a rodent model of maple syrup urine disease

    by Isabela da Silva Lemos, Sasckia Duarte, Meline Oliveira dos Santos Morais, Carolina Giassi Alano, Laura Schmidt Quinsani, Rafaela Tezza Matiola, Flávia Saccon Niero, Lucas Candido Pedro, Zilli Réus, Flavia Karine Rigo, et al.

  • Open Access

    Resveratrol improves behavior and neurochemical parameters in rats submitted to a Maple Syrup Urine Disease chemical model

    by Pauline S. Effting, Isabela S. Lemos, Bianca Z. DE Medeiros, Laura S. Quinsani, Rejane F. Seldenreich, Rafaela T. Matiola, Carolina G. Alano, Monique C. André, Gislaine Z. Réus, Guilhian Leipnitz, et al.

    Maple syrup urine disease (MSUD) is a rare genetic disorder characterized by a deficiency of the branched-chain α-keto acid dehydrogenase enzyme complex, resulting in the accumulation of branched-chain amino acids (BCAA) in the tissues and body fluids of patients. Metabolic decompensation plays a central role in MSUD neuropathology and is associated with memory impairment, cholinergic signaling alterations, and an oxidative stress state. Resveratrol is an antioxidant molecule, playing the role of a reactive species scavenger and modulating the gene expression of antioxidant enzymes. We aimed to evaluate the resveratrol effects on behavior and neurochemical parameters in rats subjected to an MSUD protocol. Animals were divided into four groups: Saline Control, BCAA Control, Saline Resveratrol, and BCAA + Resveratrol. After 21 days of administration, the open field habituation memory test, cholinergic system activity, and oxidative stress were assessed. Resveratrol was able to improve behavior parameters, protecting against the memory loss caused by the BCAA treatment, but had no effect on the cholinergic system. Additionally, resveratrol reduced oxidative damage and enhanced catalase activity. Herein, resveratrol can be an important adjuvant treatment for MSUD, as its antioxidant properties may be beneficial in the oxidative stress and cognitive impairment associated with the disease.

  • Minocycline Protects Against Oxidative Stress in a Model of Maple Syrup Urine Disease

    by Isabela da Silva Lemos, Rejane Figueiredo Seldenreich, Carolina Giassi Alano, Laura Quinsani Schmitt, Rafaela Tezza Matiola, Ellen De Pieri, Fabricia Petronilho, Ricardo Andrez Machado-De-Ávila, Emilio Luiz Streck

    Branched-chain amino acids (BCAA) leucine, isoleucine, and valine are metabolized by complex branched-chain ketoacids dehydrogenase (BCKDH). In Maple Syrup Urine Disease (MSUD), the BCKDH complex has its activity blocked by a genetic mutation, compromising the BCAA metabolism and leading to the accumulation of these BCAA, related to neurological damage in this disease. Thus, minocycline is a broad-spectrum antibiotic, bacteriostatic, and studies have shown benefits in neurodegenerative disease progression, like reduction of oxidative stress, inflammation, and downregulation of molecular pathways, such as apoptosis. Therefore, we make the hypothesis that the minocycline can ameliorate oxidative stress in the MSUD model. For this, we used 7-day-old male rats, who were treated with BCAA (leucine 393.42 mg/kg, isoleucine 121.66 mg/kg and valine 126.4 mg/kg) or saline solution (0,9%) subcutaneously, water, or minocycline (50 mg/kg) via gavage. Our results show that the MSUD group presents an increase in DCFH oxidation and TBARS levels, as well as a decrease in sulfhydryl content, related to oxidative species production, lipid and protein damage, and minocycline treatment rescues this damage found. In antioxidant activity, we found an increase in SOD activity also, a decrease in CAT in all groups studied compared to the control group. So, our results present positive effects of minocycline in MSUD, showing a potential use in this disease; moreover, more studies are necessary to understand the role of this molecule in this disease.